Baqsimi is a Synthetic Peptide owned by Eli Lilly and Co, and is involved in 13 clinical trials, of which 12 were completed, and 1 is ongoing.

Glucagon works by enhancing the activity of glucagon receptor. Glucagon receptor is a G protein-coupled receptor located in the plasma membrane. The drug candidate initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme activates phosphorylase kinase which in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood.

The revenue for Baqsimi is expected to reach a total of $6.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Baqsimi NPV Report.

Baqsimi is currently owned by Eli Lilly and Co.

Baqsimi Overview

Glucagon (Baqsimi) is an anti hypoglycemic agent. It is formulated as powder for inhalational route of administration. Baqsimi is indicated for the treatment of severe hypoglycemia in patients with diabetes ages 4 years and above.

Glucagon (LY-900018, AMG-5041) is under development for the treatment of severe hypoglycemia in type 1 and type 2 diabetes patients. The drug candidate is administered through intranasal route. It acts by targeting the glucagon receptor. The drug candidate is a new biological entity (NBE). It was also under development for the treatment of common cold.

Eli Lilly and Co Overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

The company reported revenues of (US Dollars) US$28,318.4 million for the fiscal year ended December 2021 (FY2021), an increase of 15.4% over FY2020. In FY2021, the company’s operating margin was 21%, compared to an operating margin of 24.7% in FY2020. In FY2021, the company recorded a net margin of 19.7%, compared to a net margin of 25.2% in FY2020. The company reported revenues of US$6,941.6 million for the third quarter ended September 2022, an increase of 7% over the previous quarter.

Quick View – Baqsimi

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Baqsimi
Administration Pathway
  • Nasal
Therapeutic Areas
  • Ear Nose Throat Disorders
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.